
https://www.science.org/content/blog-post/what-s-it-worth-you
# What's It Worth to You? (February 2006)

## 1. SUMMARY

This commentary from February 2006 examines cancer drug pricing by discussing a New York Times article about monoclonal antibody therapies including Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), and Tarceva (erlotinib). The article focused on drug manufacturers shifting their pricing rationale from traditional research and development cost recovery to a "value-based" argument that expensive cancer therapies should be priced according to the inherent value of life-sustaining treatment.

The author notes that these antibody therapies cost tens of thousands of dollars annually while providing only months of additional life extension. The piece includes a case study of an 87-year-old man with pancreatic cancer who declined Tarceva treatment due to $1,000 monthly co-payments, questioning whether the marginal survival benefit justified the cost. The author suggests that this pricing model might be more defensible for drugs that provide years rather than months of additional life.

## 2. HISTORY

In the two decades since this article, the value-based pricing debate has intensified significantly.

**Growth in Cancer Drug Pricing:**
Cancer drug prices have continued their upward trajectory, with average monthly costs for new cancer therapies often exceeding $10,000-$15,000 (2019-2024 figures). The $40,000 annual cost mentioned for Herceptin in 2006 would now be considered relatively moderate.

**Regulatory and Policy Developments:**
- The Affordable Care Act (2010) introduced essential health benefits requiring insurance coverage for cancer treatments
- FDA expedited approval pathways expanded (2012 Breakthrough Therapy designation)
- Value frameworks emerged: ASCO Value Framework (2015), NCCN Evidence Blocks (2016), ICER assessments
- Medicare Part D coverage gap closed by 2020 under ACA provisions

**Drug Development Outcomes:**
**Successes:**
- Herceptin: Became standard of care for HER2-positive breast cancer; biosimilars entered market (2019+) creating pricing competition
- Avastin: Expanded approvals across multiple cancers; annual global sales peaked around $7 billion annually
- These drugs proved effectiveness in larger populations than initially approved

**Clinical Evolution:**
- Immunotherapy emergence (pembrolizumab approved 2014, nivolumab 2015) introduced new pricing models
- Combination therapies became standard, adding cost layers
- Precision medicine advancements allowed better patient selection, improving cost-effectiveness
- Biosimilar competition emerged starting around 2019 for some antibody therapies

**Financial Impact:**
- Patient bankruptcy rates increased among cancer patients despite insurance coverage
- High-deductible health plans became more common, increasing out-of-pocket burden
- Patient assistance programs expanded from manufacturers but gaps remained
- "Financial toxicity" became recognized as a clinical outcome in cancer care

## 3. PREDICTIONS

• **Prediction: Society would need to "fix a price for two extra months of life"**
  - **Outcome: Partial fulfillment.** Cost-effectiveness analysis became more sophisticated with QALY (quality-adjusted life year) metrics, but society never established clear consensus on monetary value of life extension. ICER typically references $100,000-$150,000 per QALY as acceptable threshold, though this remains controversial and varies by country's healthcare system.

• **Prediction: Drugs providing "years or decades" would justify "society should suck it up" pricing**
  - **Outcome: Mixed.** Cures did emerge for some cancers (hepatitis C drugs sofosbuvir 2013, CAR-T cell therapies from 2017), and these commanded premium pricing. However, incremental benefits continued to dominate, and pricing remained high across all benefit levels. The breakthrough therapies validated high pricing but didn't solve the fundamental tension between innovation incentives and access.

• **Implicit prediction: Value-based pricing would become more established**
  - **Outcome: Realized.** Pharmaceutical industry widely adopted value-based messaging by late 2010s. However, the pricing approach became more nuanced: manufacturers justified prices through clinical trial evidence packages, health economic modeling, and international reference pricing rather than simple R&D cost-plus models.

## 4. INTEREST

Rating: **8/10**

The article identified the fundamental tension in cancer drug economics that has only intensified over two decades: how to balance innovation incentives with affordability and equity. Selecting 4/5 because it captured a pivot point in pharmaceutical industry argumentation and anticipated core debates that remain unresolved in oncology pricing today.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20060216-what-s-it-worth-you.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_